. One important factor is the widespread use of novel steroid medications to manage chronic diseases in an ageing society 1, 3 . Novel drugs targeting common disorders (for example, hypertension or cancer) interfere with adrenal steroid synthesis or metabolism and have the potential to induce adrenal suppression. Here, we comment on evidence and mechanisms related to medi cations that induce adrenal insufficiency. Furthermore, we suggest steps to be taken to tackle this problem.
Steroid hormone synthesis inhibitors
Common malignancies, such as prostate or breast cancer, are treated with hormonal deprivation therapy. However, in tumours refractory to the standard treat ments, novel selective steroid hormone synthesis inhibi tors show promise. For example, 17α hydroxylase (CYP17A1) inhibitors (abiraterone for prostate cancer) can suppress androgen production but also induce cor tisol deficiency 4 . Patients treated with these inhibitors require glucocorticoid replacement therapy to avoid adrenal crisis, to lower progesterone and aldosterone accumulation and to decrease hypertension. However, such replacement therapy (up to 10-20 mg prednisone) exposes patients to excess glucocorticoids and the risk of acute adrenal crisis 4 . In the future, more potent inhibitors of androgen production might be developed. For example, in 2018, a phase I clinical trial was commenced to investigate novel selective cholesterol side chain cleavage inhibitors for prostate cancer 5 . However, this drug will induce a com plete blockade of the production of all major steroids, including cortisol, aldosterone and androgens. All treated patients will require hormone replacement therapy and should be trained in prevention of adrenal crisis.
Aldosterone synthase (CYP11B2) inhibition has the pot ential to prevent metabolic, cardiac and renal dysfunc tion in patients with the metabolic syndrome 6 . However, at higher doses, these compounds induce a general inhibi tion of 11β hydroxylase activity, which lowers aldosterone and cortisol production. Once these medications enter widespread clinical use, adrenal function, particularly during stress, should be monitored (Box 1).
Checkpoint inhibitors
Many patients with advanced skin tumours and other solid tumours as well as haematological malignancies are now being treated with immune checkpoint inhibi tors (ICIs; antibodies that block key immune check point proteins, such as CTLA4 or PD1). However, it has become apparent that ICI induced endocrinopathies are a frequent adverse effect of these medications. Over 50% of these endocrinopathies involve an impairment of HPA axis function 7 (Box 1). Of note, appropriate immune-endocrine crosstalk is crucial for the function of the adrenal stress axis 1 . For example, inflammatory cytokines (such as IL1, IL6 and TNF) regulate the HPA axis. Immune cells interact directly with corti cotrophs as well as adrenal cells. In addition, adrenal cells express Toll like receptors and chemokine recep tors that facilitate the immune-adrenal response during inflammation 1 . Inflammation, sepsis and autoimmune disease are known to induce adrenal insufficiency 1 . Unsurprisingly, ICIs can also have a major effect on HPA axis function. The HPA axis might also be disrupted by inflammation of the pituitary gland, which blunts adrenocorticotropic hormone (ACTH) release, or, less commonly, ICIs might directly impair the adrenal gland 1, 7 . The mechanisms of HPA axis dysregulation are not fully explored. However, data suggest that blocking expression of CTLA4 on endo crine cells (for example, by ipilimumab treatment) leads to site specific deposition of complement components, pituitary infiltration and hypophysitis 7 . Alarmingly, an increase has occurred in the num ber of reports of adrenal crisis in patients treated with . If hypothyroidism is treated before steroid replacement, then severe adrenal crisis might occur.
Multiple drug interactions
Novel medications that might have a low or moderate risk of inducing full adrenal insufficiency in patients with an intact HPA axis have the risk of causing substan tial damage in patients with a partially or subclinically impaired adrenal stress response. For example, in our ageing society, it is reported that >5% of the population have been exposed to glucocorticoid treatment and will have suppressed HPA axis function 1 .
The most common cause of HPA axis failure is sys temic glucocorticoid administration. For example, data confirm a clear dose dependency of iatrogenic gluco corticoid excess and adrenal insufficiency 3 . By con trast, co prescribing of low dose steroids (for example, inhaled fluticasone) together with medications inhibi ting CYP3A4 (for example, ritonavir) substantially potentiates exposure to steroids and might induce long term secondary adrenal insufficiency. Drugs that lower cholesterol (the substrate for steroid biosynthesis) levels (for example, statins or the potent PCSK9 inhibitors) do not affect adrenal steroidogenesis under normal condi tions. However, they might contribute to adrenal insuf ficiency under stress or in combination with other drugs that affect steroid metabolism 8 . Patients with hepatitis or liver disease have impaired adrenal function. For example, a substantial proportion of patients with alcoholic liver disease have impaired adrenal function, as do patients with chronic infections (for example, viral hepatitis, HIV or Mycobacterium tuberculosis) 1 . In addition, up to 30% of patients receiv ing opioids have a suppressed HPA axis 9 . Opioids exert a tonic inhibition on the HPA axis, blocking hypo thalamic corticotropin releasing hormone (CRH) release and subsequent ACTH and cortisol produc tion. Finally, we are beginning to learn more about environmental endocrine disruptors and chemicals that block adrenal steroid production and predispose to an impaired HPA axis 10 
(Box 1).
What needs to be done? First, we should raise awareness about this problem among the endocrine community and among health care professionals. Second, patients on these medications (Box 1) should be equipped with an emergency identifi cation card and a kit for self treatment of adrenal insuf ficiency. Education and training of patients, their carers and relatives (as required for patients with Addison disease) should be offered. Third, we should develop appropriate test systems to explore the effects of novel medications on HPA axis function. Finally, we suggest the development of a digital application using a machine learning algorithm to help health care professionals assess risk for adrenal insufficiency in their patients.
